0001209191-17-042008.txt : 20170627 0001209191-17-042008.hdr.sgml : 20170627 20170627174154 ACCESSION NUMBER: 0001209191-17-042008 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20170624 FILED AS OF DATE: 20170627 DATE AS OF CHANGE: 20170627 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Cascadian Therapeutics, Inc. CENTRAL INDEX KEY: 0001412067 STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-COMMERCIAL PHYSICAL & BIOLOGICAL RESEARCH [8731] IRS NUMBER: 260868560 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 2601 FOURTH AVENUE STREET 2: SUITE 500 CITY: SEATTLE STATE: WA ZIP: 98121 BUSINESS PHONE: (206) 801-2100 MAIL ADDRESS: STREET 1: 2601 FOURTH AVENUE STREET 2: SUITE 500 CITY: SEATTLE STATE: WA ZIP: 98121 FORMER COMPANY: FORMER CONFORMED NAME: Oncothyreon Inc. DATE OF NAME CHANGE: 20070927 FORMER COMPANY: FORMER CONFORMED NAME: Biomira CORP DATE OF NAME CHANGE: 20070911 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: SPIEGELMAN DANIEL K CENTRAL INDEX KEY: 0001238403 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-33882 FILM NUMBER: 17933268 MAIL ADDRESS: STREET 1: C/O BIOMARIN PHARMACEUTICAL INC. STREET 2: 105 DIGITAL DRIVE CITY: NOVATO STATE: CA ZIP: 94949 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2017-06-24 0 0001412067 Cascadian Therapeutics, Inc. CASC 0001238403 SPIEGELMAN DANIEL K C/O CASCADIAN THERAPEUTICS, INC. 2601 FOURTH AVE., SUITE 500 SEATTLE WA 98121 1 0 0 0 Common Stock 2017-06-24 4 M 0 9058 0.00 A 21490 D Common Stock 2017-06-24 4 F 0 2265 3.78 D 19225 D Restricted Share Unit (RSU) 2017-06-24 4 M 0 9058 0.00 D Common Stock 9058 0 D 2,265 shares of the restricted share unit ("RSU") grant, which represent approximately 25% of the shares underlying the RSU grant that vested on June 24, 2017, were not issued to the reporting holder; instead the reporting holder received an amount in cash from the issuer equal to the value of such shares based on the closing price of the issuer's Common Stock on June 23, 2017, the most recent date prior to the vesting date on which the issuer's Common Stock was traded, to facilitate such holder's satisfaction of U.S. federal income tax obligations in connection with the vesting of the RSUs, which transaction does not represent a sale by the reporting person. Approximately 75% of each RSU represents a contingent right to receive approximately 0.75 share of the issuer's Common Stock upon vesting and approximately 25% represents a contingent right to receive cash upon vesting, which cash will be used to facilitate such holder's satisfaction of U.S. federal income tax obligations in connection with the vesting of the RSUs. The RSU was 100% vested on June 24, 2017. /s/ Julia M. Eastland as attorney-in-fact for Daniel K. Spiegelman 2017-06-27